In Brief This Week: PerkinElmer; DaVita, Roche; Unilabs, BGI; Intrexon; Agilent; Danaher; Sigma-Aldrich; GE Healthcare | GenomeWeb

NEW YORK (GenomeWeb News) – PerkinElmer reduced its headcount by 17 in the first quarter as part of a restructuring plan, it said in its Form 10-Q this week. The company recognized pre-tax restructuring charges of $400,000 and $200,000 in its Human Health segment and Environmental Health segment, respectively, as a result. PerkinElmer also shut down its Signature Genomics business subsequent to the end of the first quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.